CN Patent

CN102471324B — 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物

Assigned to Janssen R&D Ireland ULC · Expires 2014-12-17 · 11y expired

What this patent protects

式(I)的HCV复制抑制剂，包括其立体化学异构体形式和盐、水合物、溶剂合物，其中R和R’具有说明书限定的含义。本发明还涉及制备所述化合物的方法、含有它们的药用组合物，及其单独或与其它HCV抑制剂组合在HCV疗法中的用途。

USPTO Abstract

式(I)的HCV复制抑制剂，包括其立体化学异构体形式和盐、水合物、溶剂合物，其中R和R’具有说明书限定的含义。本发明还涉及制备所述化合物的方法、含有它们的药用组合物，及其单独或与其它HCV抑制剂组合在HCV疗法中的用途。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN102471324B
Jurisdiction: CN
Classification: —
Expires: 2014-12-17
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.